SCHEMBL335356

SCHEMBL335356

C[C@H]1OC1OCc1ccccc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.44
IDO1 P14902 1/20 0.41
PDPK1 O15530 1/20 0.41
MTOR P42345 1/20 0.41
FGF1 P05230 2/20 0.40
FGF2 P09038 2/20 0.40
VEGFA P15692 2/20 0.40
HPSE Q9Y251 2/20 0.40
AGXT P21549 1/20 0.40
CTSL P07711 1/20 0.40
CTSB P07858 1/20 0.40
CTSK P43235 1/20 0.40
ALDH1A1 P00352 2/20 0.39
MAPT P10636 2/20 0.39
CYP2C19 P33261 1/20 0.39
OPRM1 P35372 1/20 0.39
OPRL1 P41146 1/20 0.39
MAPK1 P28482 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4621113 1.00 TSHR (0.44) TSHRIDO1PDPK1MTORFGF1
SCHEMBL7775231 0.82 PDPK1 (0.45) TSHRPDPK1MTORFGF1FGF2
SCHEMBL24378456 0.82 PDPK1 (0.47) TSHRIDO1PDPK1MTORAGXT
SCHEMBL7133576 0.81 SLC5A2 (0.45) MAPTMAPK1
SCHEMBL20643537 0.81 SLC5A2 (0.45) MAPTMAPK1
SCHEMBL15671094 0.81 SLC5A2 (0.45) MAPTMAPK1
SCHEMBL3642166 0.81 SLC5A2 (0.45) MAPTMAPK1
SCHEMBL7154852 0.81 SLC5A2 (0.45) MAPTMAPK1
SCHEMBL18573748 0.80 PDPK1 (0.50) TSHRIDO1PDPK1MTORAGXT
SCHEMBL29524151 0.80 TK1 (0.41) IDO1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8097708-B2 10a-Azalide compound TAISHO PHARMACEUTICAL CO., LTD. (JP) 2012-01-17 US disclosed
US-20090281292-A1 10a-Azalide Compound MEIJI SEIKA PHARMA CO., LTD. (JP) 2009-11-12 US disclosed
EP-1985620-A1 10a-AZALIDE COMPOUND TAISHO PHARMACEUTICAL CO., LTD (JP) 2008-10-29 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090281292-A1 10a-Azalide Compound IL17A, AZI2, HDAC9 TSHR 1567/4885IDO1 1290/4885PDPK1 4619/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.